Posted by Michael Wonder on 09 Oct 2024
Biogen receives US FDA breakthrough therapy designation for felzartamab for the treatment of antibody mediated rejection in kidney transplant recipients
9 October 2024 - Designation is based on data from the clinical development program which demonstrated clinical proof of concept.
Biogen announced today that felzartamab, an investigational anti-CD38 monoclonal antibody, has received breakthrough therapy designation from the US FDA for the treatment of late antibody mediated rejection without T cell mediated rejection in kidney transplant patients.
